Bellicum Pharmaceuticals reports Q4 EPS (66c), consensus (70c)
Bellicum reported a net loss of $21.9M for the fourth quarter of 2017 and $91.8M n for the year ended December 31, compared to a net loss of $19.9M and $69.2M for the comparable periods in 2016. The results included non-cash, share-based compensation charges of $3.4M and $13.6M for the fourth quarter and year ended December 31, 2017, respectively, and $3.1M and $12.3M for the comparable periods in 2016. Bellicum ended the year on December 31 with cash, restricted cash and investments totaling $106.5M, compared to $113.4M at December 31, 2016. In the fourth quarter of 2017, the company paid off its Hercules Capital debt facility with a $35Mn loan from Oxford Finance. The new loan provided approximately $2.1M in additional liquidity, interest-only payments until February 1, 2020 and a lower interest rate. Based on current operating plans, Bellicum expects that current cash resources will be sufficient to meet operating requirements through the first quarter of 2019.